Kalpana Kalpana (Editor)

Trophogen

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Industry
  
Biotechnology

Number of employees
  
7 (2013)

Founded
  
2001

Type of business
  
Private

Trophogen wwwtrophogencomex3imagesHeading20Trophogenpng

Key people
  
Bruce Weintraub, COO & CSO Mariusz Szkudlinski, VP Research and Development

Headquarters
  
Rockville, Maryland, United States

Trophogen, Inc. is a biotechnology company based in Rockville, Maryland.

Contents

Company was founded in 2001 with Series A funding from Toucan Capital, focusing on the development of human and bovine high affinity glycoprotein hormone and related growth factor superagonist analogs for human infertility and animal superovulation as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.

Technology

The key to Trophogen's long acting superagonist proprietary patented technology is to carefully engineer new analogs to increase their affinity to the receptor. This is achieved by substituting crucial amino acids in the receptor binding domain, increasing affinity up to 100 fold. The addition of neoglycosylation sites extends the half-life of those analogs without extensions or subunit linkers, improving treatment convenience by reducing the number of injections. Trophogen's technology represents the first successful design of super active analogs of glycoprotein hormones that shows major increases in bioactivity and far exceeds results shown for other protein ligands

Lead product candidates

  1. Recombinant, long acting, high potency human FSH superagonist analog for infertility and elective egg banking.
  2. Recombinant, long acting, high potency human TSH superagonist analog for imaging and treatment of thyroid cancer.
  3. Recombinant, long acting, high potency bovine FSH superagonist analog for superovulation and embryo transfer in beef and dairy cows.
  4. Recombinant, long acting, high potency equine CG superagonist analog for superovulation and embryo transfer in pigs.
  5. Recombinant, long acting, high potency human VEGF superagonist for imaging and therapy of thyroid and multiple other cancers.
  6. Recombinant, long acting, high potency human LH superagonist for infertility therapy.
  7. Recombinant, long acting, high potency bovine LH superagonist analog for maintenance of pregnancy in beef and dairy cows.
  8. Recombinant, long acting, high potency VEGF superagonist for imaging and therapy of thyroid and other cancers in dogs and other animals.

References

Trophogen Wikipedia